(Q42290948)

English

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

scientific article published on 17 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Adaptive radiation therapy

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Daphna Gelblum

8

0 references

author name string

Matthew G Fury

1

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Han Xiao

2

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Eric J Sherman

3

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Shrujal Baxi

4

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Stephanie Smith-Marrone

5

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Karen Schupak

6

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Richard Gewanter

7

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Sofia Haque

9

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Heiko Schoder

10

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Jatin P Shah

11

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Nora Katabi

12

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Rachel Kurtzman

13

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Brynna Lipson

14

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Lisa Cox

15

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Nancy Y Lee

16

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

David G Pfister

17

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 March 2015

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

38 Suppl 1

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

E566-70

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Improved survival with bevacizumab in advanced cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Human papillomavirus and survival of patients with oropharyngeal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

26 October 2017

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

29 May 2018

A performance status scale for head and neck cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

29 May 2018

Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

17 August 2018

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5398410

17 August 2018

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1002%2FHED.24041

21 January 2018

A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25784616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25784616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25784616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium

1 reference

https://pubmed.ncbi.nlm.nih.gov/25784616

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/HED.24041

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42290948&oldid=1941321767"